BSE filing, NSE: VIMTALABS. Summary written from the filing by ALFA Finder's alert engine.
Vimta Labs Ltd: key numbers
- Share price
- ₹510.00
- Market cap
- ₹2,280 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 28.6×Sector 51.1×
- Promoter holding
- 35.64%-0.03% QoQ
- FII holding
- 5.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Board Meeting Date
Vimta Labs will hold a board meeting on 30 October 2026 to consider half-year results. Trading window stays closed from 01 October.
Vimta Labs Employee Stock Options
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.
Vimta Labs Credit Rating
CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.
Vimta Labs Price Movement Clarification
Vimta Labs clarified that recent increases in its share volume are due to market factors and not related to any undisclosed company information or developments.
Vimta Labs Adverse Business Impact
Vimta Labs reported a cyber security incident affecting its IT infrastructure. The company confirmed operations remain fully functional with no material impact identified thus far.
Vimta Labs Investor Presentation: Key Takeaways
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
- Call
- Guides 25% growth
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.